SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Forsgren Lars) ;mspu:(researchreview)"

Sökning: WFRF:(Forsgren Lars) > Forskningsöversikt

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bolin, Kristian, et al. (författare)
  • The Cost Effectiveness of Newer Epilepsy Treatments A Review of the Literature on Partial-Onset Seizures
  • 2012
  • Ingår i: PharmacoEconomics (Auckland). - : Springer Science and Business Media LLC. - 1170-7690 .- 1179-2027. ; 30:10, s. 903-923
  • Forskningsöversikt (refereegranskat)abstract
    • Background and Objective: Epilepsy is one of the most common neurological disorders, affecting more than 3 million people in Europe. This paper reviews the published evidence regarding the cost effectiveness of second-generation antiepileptic drugs (AEDs). Methods: A systematic literature search was performed, using the databases Academic Search Complete, Econlit, EMBASE and MEDLINE. Health economic evaluations of newer (second-generation) AEDs, published as full-length journal articles, were searched for. We focused on evaluations of newer AEDs as treatment for partial-onset seizures. 470 studies were initially identified and 19 were finally included. Information regarding (i) AEDs studied, (ii) cost effectiveness, and (iii) a variety of health economic modelling specifics was extracted from each study. Then, the included studies were summarized and a quality assessment was performed, according to the British Medical Journal's guidelines for economic studies. Results: The results were as follows: (i) the cost per additional QALY for newer AEDs used as adjunctive treatment, compared with standard therapy, ranged between $US19 139 (levetiracetam) and $US57 210 (pregabalin) [year 2010 values]; no cost-effectiveness evidence was identified for felbamate, eslicarbazepine, oxcarbazepine or tiagabine; and (ii) all studies met at least 60% of the British Medical Journal's guidelines criteria, and seven studies were found to satisfy more than 80% of the criteria. Guidelines criteria not met involve inadequate reporting of input data and modelling details, including validation and availability of models used for cost-effectiveness calculations. Conclusions: Although failure to meet good practice guidelines influences the reliability of the presented evidence adversely, a sufficient number of the included studies were found to comply enough with the guidelines in order for the qualitative content of the cost-effectiveness results that some of the newer AEDs are cost effective to be reliable. In fact, this conclusion is likely to be relatively robust, since the effect of improved seizure control on labour market performance was not included in the base-case results in any of the included studies and improved seizure control need only to have a moderate effect on sickness absenteeism in order for the corresponding treatment to be cost effective even when willingness to pay for an additional QALY is low. However, the cost effectiveness of newer AEDs has only been studied for a small number of settings, and hence future studies incorporating additional settings are needed.
  •  
2.
  • Bridel, Claire, et al. (författare)
  • Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology : A Systematic Review and Meta-analysis
  • 2019
  • Ingår i: JAMA Neurology. - : American Medical Association (AMA). - 2168-6149 .- 2168-6157. ; 76:9, s. 1035-1048
  • Forskningsöversikt (refereegranskat)abstract
    • Importance  Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date.Objectives  To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating clinically similar conditions.Data Sources  PubMed was searched for studies published between January 1, 2006, and January 1, 2016, reporting cNfL levels (using the search terms neurofilament light and cerebrospinal fluid) in neurological or psychiatric conditions and/or in HC.Study Selection  Studies reporting NfL levels measured in lumbar CSF using a commercially available immunoassay, as well as age and sex.Data Extraction and Synthesis  Individual-level data were requested from study authors. Generalized linear mixed-effects models were used to estimate the fixed effects of age, sex, and diagnosis on log-transformed NfL levels, with cohort of origin modeled as a random intercept.Main Outcome and Measure  The cNfL levels adjusted for age and sex across diagnoses.Results  Data were collected for 10 059 individuals (mean [SD] age, 59.7 [18.8] years; 54.1% female). Thirty-five diagnoses were identified, including inflammatory diseases of the central nervous system (n = 2795), dementias and predementia stages (n = 4284), parkinsonian disorders (n = 984), and HC (n = 1332). The cNfL was elevated compared with HC in a majority of neurological conditions studied. Highest levels were observed in cognitively impaired HIV-positive individuals (iHIV), amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and Huntington disease. In 33.3% of diagnoses, including HC, multiple sclerosis, Alzheimer disease (AD), and Parkinson disease (PD), cNfL was higher in men than women. The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC. The cNfL overlapped in most clinically similar diagnoses except for FTD and iHIV, which segregated from other dementias, and PD, which segregated from atypical parkinsonian syndromes.Conclusions and Relevance  These data support the use of cNfL as a biomarker of neuroaxonal damage and indicate that age-specific and sex-specific (and in some cases disease-specific) reference values may be needed. The cNfL has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.
  •  
3.
  • Forsgren, Lars, et al. (författare)
  • Neurogenetik
  • 2004
  • Ingår i: Incitament. ; , s. 25-28
  • Forskningsöversikt (populärvet., debatt m.m.)
  •  
4.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4
Typ av publikation
Typ av innehåll
refereegranskat (2)
övrigt vetenskapligt/konstnärligt (1)
populärvet., debatt m.m. (1)
Författare/redaktör
Forsgren, Lars (4)
Blennow, Kaj, 1958 (1)
Zetterberg, Henrik, ... (1)
Kuhle, Jens (1)
Wallin, Anders, 1950 (1)
Gisslén, Magnus, 196 ... (1)
visa fler...
Landén, Mikael, 1966 (1)
Lycke, Jan, 1956 (1)
Bolin, Kristian (1)
Khademi, Mohsen (1)
Olsson, Tomas (1)
Piehl, Fredrik (1)
Wikkelsö, Carsten, 1 ... (1)
Johannsson, Gudmundu ... (1)
Hansson, Oskar (1)
Janelidze, Shorena (1)
Teunissen, Charlotte ... (1)
Leinonen, Ville (1)
Axelsson, Markus, 19 ... (1)
Svenningsson, Anders (1)
Christensen, Jeppe R ... (1)
Paterson, Ross W (1)
Schott, Jonathan M (1)
Burman, Joachim, 197 ... (1)
Andreasson, Ulf, 196 ... (1)
Gunnarsson, Martin, ... (1)
Brundin, Lou (1)
Morozova-Roche, Ludm ... (1)
Verbeek, Marcel M (1)
Ragnarsson, Oskar (1)
Mattsson, Niklas (1)
Skillbäck, Tobias (1)
van Swieten, John C (1)
Visser, Pieter Jelle (1)
Bjerke, Maria (1)
Hall, Sara (1)
Malaspina, Andrea (1)
Turner, Martin R (1)
Boxer, Adam (1)
Jonsson, Michael, 19 ... (1)
Wild, Edward J (1)
Rojas, Julio C. (1)
Sandberg, Linda (1)
Bridel, Claire (1)
van Wieringen, Wesse ... (1)
Tijms, Betty M. (1)
Alvarez-Cermeno, Jos ... (1)
Backstrom, David C. (1)
Bartos, Ales (1)
Christensen, Tove (1)
visa färre...
Lärosäte
Umeå universitet (2)
Uppsala universitet (2)
Göteborgs universitet (1)
Örebro universitet (1)
Lunds universitet (1)
Karolinska Institutet (1)
Språk
Svenska (2)
Engelska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (2)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy